In this issue of Hematology/Oncology Clinics, guest editors Drs. Jorge J. Castillo, Prashant Kapoor, and Shayna Sarosiek bring their considerable expertise to the topic of Waldenström Macroglobulinemia. Top experts in the field provide a focused update on the biology, diagnosis and management, and novel therapies for patients with Waldenström macroglobulinemia, a rare blood cell cancer characterized by an excess of abnormal white blood cells in the bone marrow.
Clinical Implications of Genomic Profile in Waldenström Macroglobulinemia Frontline Management of Waldenström Macroglobulinemia with Chemoimmunotherapy Proteasome Inhibitor-Based Regimens in the Frontline Management of Waldenström Macroglobulinemia BTK Inhibitors in the Frontline Management of Waldenström Macroglobulinemia Future Directions in the Frontline Management of Waldenström Macroglobulinemia The Management of Relapsed or Refractory Waldenströms Macroglobulinemia Novel Agents in Waldenström Macroglobulinemia Investigation and Management of Immunoglobulin M- and Waldenström-Associated Peripheral Neuropathies Evaluation and Management of Bing-Neel Syndrome Evaluation and Management of Disease Transformation in Waldenström Macroglobulinemia Management of Waldenström Macroglobulinemia in Limited-Resource Settings
Comments (0)
Your review appreciation cannot be sent
Report comment
Are you sure that you want to report this comment?
Report sent
Your report has been submitted and will be considered by a moderator.